Clinicopathological Correlation with Outcome of Diffuse Large B Cell Lymphoma: Experience in a Specialized Cancer Care Centre in Bangladesh

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the world, and accounts for 30%–40% of all adult NHLs. It is clinically, morphologically and genetically a heterogeneous group of tumors composed of large B cells. This study aimed to determine the clinical features, treatment options, the response rate in a specialized cancer care centre.
 Methods: This retrospective study included all DLBCL patients registered in the department of Haematology of National Institute of Cancer Research and Hospital (NICR&H), Bangladesh between July 2016 to June 2019.
 Results: A total of 151cases were included in this study. The mean age was 47 years with a standard deviation (SD) of 15 years. Males (66.2%) were more in the occurrence of DLBCL. We divided the cases into three different entities of DLBCL and non-germinal centre B (non-GCB) variety was the prevalent (46.4%) one. Several types of first-line chemotherapy were used in management and the overall response rate (ORR) was 76.6% and 9.2% of death. The response was found to be significant with B symptoms, stage, and international prognostic index (IPI) score. But no significant difference was observed in outcome among different types of DLBCL after treatment.
 Conclusion: This retrospective study will help to ascertain the co relation of DLBCL outcome with clinicopathological profile. (edited)
 J MEDICINE JAN 2021; 22 (1) : 3-6

Clinicopathological features of relapsed diffuse large B-cell lymphoma: South Egypt Cancer Institute experience

“…Relapsed DLBCL is defined according to Cheson criteria [5] by the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites or ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the Sum of product of diameter (SPD) of more than one node. Several clinical and pathological factors such as patient's age, clinical stage, performance status, tumor extension, histological variant, bone marrow involvement, international prognostic index (IPI), molecular phenotype (GCB versus non-GCB), biochemical and immunohistochemical markers can predict the outcome after chemotherapy [6]. This study aims to 1-Assess the clinicopathological characteristics of relapsed DLBCL, NOS.…”